Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Camurus AB (publ) is a Swedish science-led biopharmaceutical company founded in 1991 and headquartered in Lund, specializing in the research, development, and commercialization of innovative, long-acting medicines for severe and chronic diseases. The company leverages its proprietary FluidCrystal technology, which utilizes lipid lyotropic liquid crystal nanostructures to enable controlled, sustained release of active pharmaceutical ingredients such as peptides, proteins, and small molecules. This platform supports injectable depots for extended therapeutic delivery from a single dose and topical bioadhesive systems for local treatment. Camurus addresses critical unmet needs in areas including opioid dependence with products like Buvidal and Brixadi, acromegaly with Oczyesa, pain management, cancer, endocrine disorders, oncology supportive care, metabolic diseases, and rare conditions. With over 250 employees across offices in Europe, the US, and Australia, Camurus collaborates with global pharmaceutical partners like Novartis and Braeburn to advance its diversified clinical pipeline, enhancing patient outcomes, treatment adherence, and quality of life through best-in-class potential therapies.
kr 539.78
+kr 1.11 (+0.21%)
Live · 05:18 PM · Twelve Data
Margins and capital returns are both well above average: 38.58% operating margin, ROIC at 18.01%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 21.3% YoY with margins expanding 13.8pp.
At 48x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
47.6x earnings, 39.9x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 2.24B
▲ +21.3% YoY
Net Income (TTM)
kr 682M
▲ +71.7% YoY
Op. Margin
35.86%
▲ +13.8pp YoY
ROIC
18.01%
▲ +3.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 810M
▲ +103.8% YoY
Op. Cash Flow (TTM)
kr 883M
▲ +113.2% YoY
Net Debt
-kr 3.62B
Net Cash Position
Cash & Equiv.
kr 3.73B
3Y CAGR: +33.3%
3Y CAGR: +94.5%
Continue Research
At a P/E of 47.6 and a price-to-free-cash-flow of 39.9, Camurus AB (publ) (CAMX.XSTO) trades below a two-stage DCF intrinsic value of about SEK 743.89 per share, so at SEK 539.78 the stock looks undervalued (37.8% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Camurus AB (publ) scores 73/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 743.89 per share for CAMX.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 557.92. At today's SEK 539.78, that puts the stock about 37.8% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Camurus AB (publ) scores 73 out of 100 on Intrinsiqq's quality score, passing 5 of 8 checks, which makes it a solid business on these measures. Recent fundamentals include a 35.9% operating margin and a 18.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. CAMX.XSTO currently trades below its estimated intrinsic value and scores 73/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.